Table 1.
Demographic characteristics and comparison between CSU and CINDU.
| Total | CSU | CINDU | P | |
|---|---|---|---|---|
| Mean (median)±SD | Mean (median)±SD | Mean (median)±SD | ||
| Gender | ||||
| Female n (%) | 108 (67.9%) | 57 (70.4%) | 51 (65.4%) | 0.501 |
| Age (years) | 39.1 (39) ± 13.3 | 40.5 (38) ± 14 | 37.7 (39) ± 12,5 | 0.328 |
| Min-max | 14–75 | 14–75 | 17–72 | |
| Disease duration (mo) | 33.8 (12) ± 59.3 | 31.5 (9) ± 67.9 | 36.324 ± 49.1 | 0.007 |
| Min-max | 2–480 | 2–480 | 2–240 | |
| UAS28-Baseline | 42.728 ± 36.4 | – | ||
| Min--max | 0–127 | |||
| UAS28-1st | 34.3 (23) ± 37.6 | – | ||
| Min-max | 0–165 | |||
| UCT-1st | 9.5 (9) ± 3.8 | 10.4 (11) ± 3.9 | 8.48 ± 3.4 | 0.001 |
| Min-max | 1–16 | 1–16 | 1–16 | |
| UCT-2nd | 11.6 (12) ± 3.3 | 11.7 (12) ± 3.4 | 11.412 ± 3.2 | 0.379 |
| Min-max | 2–16 | 2–16 | 2–16 | |
| CU-Q2oL-1st | 22.7 (17.3) ± 19.5 | – | ||
| Min-max | 0–79.34 | |||
| CU-Q2oL-2nd | 18.5 (14.1) ± 18.0 | – | ||
| Min-max | 0–73.90 | |||
| PatGA-VAS-1st | 4.0 (4.5) ± 2.8 | 3.1 (2) ± 2.7 | 4.95 ± 2.5 | <0.001 |
| Min-max | 0–10 | 0–10 | 0–10 | |
| PatGA-VAS-2nd | 3.1 (2) ± 2.7 | 2.5 (1.5) ± 2.7 | 3.83 ± 2.7 | 0.001 |
| Min-max | 0–10 | 0–9 | 0–10 | |
| PhyGA-VAS-1st | 6.8 (6) ± 5.6 | 8.1 (8) ± 7.4 | 5.55 ± 2.2 | <0.001 |
| Min-max | 1–7 | 2–7 | 1–10 | |
| PhyGA-VAS-2nd | 7.2 (8) ±2.6 | 7.7 (9) ± 2.4 | 6.6 (7.5) ± 2.6 | 0.003 |
| Min-max | 1–10 | 1–10 | 1–10 | |
| Pat ATR-1st n,% - treatment sufficient | 82 (51.6%) | 53 (65.4%) | 29 (37.2%) | <0.001 |
| Pat ATR-2nd n,%- treatment sufficient | 105 (66%) | 55 (67.9%) | 50 (64.1%) | 0.613 |
| PHY ATR-1st n,%- treatment sufficient | 71 (44.7%) | 52 (64,2%) | 19 (24,4%) | <0.001 |
| PHY ATR-2nd n,%-treatment sufficient | 106 (66.7%) | 56 (69.1%) | 50 (64.1%) | 0.501 |
| DLQI-1st m (md±SD) | – | 8.57 ± 6.3 | ||
| Min-max | 0–24 | |||
| DLQI-2nd m (md±SD) | 5.74 (4) ±6.26 | |||
| Min-max | 0–27 |
Pearson Chi-Square, Mann-Whitney U.
UAS28-Baseline: the 4-weekly UAS score before the 1st visit, UAS28, UAS28-1st: the 4-weekly UAS score between the 1st and 2nd visit, UCT-1st: Urticaria control test score at the 1st visit, UCT-2nd: Urticaria control test score at the 2nd visit, CU-Q2oL-1st: Chronic urticaria quality of life questionnaire score at the 1st visit, CU-Q2oL-2nd: Chronic urticaria quality of life questionnaire score at the 2nd visit, PatGA-VAS-1st: Patient's global assessment of disease severity-visual analog scale at the 1st visit, PatGA-VAS-2nd: Patient's global assessment of disease severity-visual analog scale at the 2nd visit, PhyGA-VAS-1st: Physician's global assessment of disease control - visual analog scale at the 1st visit, PhyGA-VAS-2nd: Physician's global assessment of disease control - visual analog scale at the 2nd visit, DLQI-1st: Dermatology Life Quality Index Score at the 1st visit, DLQI-2nd: Dermatology Life Quality Index Score at the 2nd visit.